The situation surrounding the COVID-19 pandemic is rapidly evolving and Nilogen Oncosystems remains committed to advance IO research during this challenging time. Our labs are open, and we are preparing tumor organoids from fresh patient tumor tissue for all platforms and assay services, including tumor cell killing, multiplex cytokine analysis, flow cytometry and multiplex immunofluorescence supported by integrated bioinformatics capabilities.
That way, in the paper you understand that the primary idea is sound.
We have experienced a slowdown in tissue procurement but anticipate that all our US tissue procurement partners/teaching hospitals will be back up to speed in early June.
The safety of our customers and employees is important to us. We are taking precautions to prevent the spread of COVID-19 and will continue to do so following federal, state, CDC, ECDC, and WHO guidelines. We have implemented a company-wide travel restriction for domestic and international travel.
We will continue to monitor the COVID-19 situation and provide updates as needed.